Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 3/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19465313 | 1.00 | HPGD (0.46) | HPGDHTTSMN1; SMN2GLP1RMEN1 | |
| SCHEMBL13567279 | 0.87 | HPGD (0.43) | HPGDHTTSMN1; SMN2GLP1RMEN1 | |
| SCHEMBL16976283 | 0.85 | HPGD (0.40) | HPGDHTTSMN1; SMN2GLP1RMEN1 | |
| SCHEMBL29467571 | 0.83 | HPGD (0.45) | HPGDHTTSMN1; SMN2GLP1RTLR2 | |
| SCHEMBL13566481 | 0.83 | GLP1R (0.58) | HPGDHTTSMN1; SMN2GLP1RMEN1 | |
| SCHEMBL19465297 | 0.83 | GLP1R (0.58) | HPGDHTTSMN1; SMN2GLP1RMEN1 | |
| SCHEMBL19732507 | 0.79 | SMN1; SMN2 (0.51) | HPGDHTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL2601767 | 0.79 | SMN1; SMN2 (0.53) | HPGDHTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL17885894 | 0.79 | SMN1; SMN2 (0.48) | HPGDHTTSMN1; SMN2GLP1RMEN1 | |
| SCHEMBL17168610 | 0.78 | SMN1; SMN2 (0.44) | HPGDHTTSMN1; SMN2GLP1RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180156810-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9791450-B2 | Fluorescent compounds | BIOTIUM, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160033520-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9097667-B2 | Fluorescent compounds | BIOTIUM, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20090305410-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305410-A1 | FLUORESCENT COMPOUNDS | MKI67, CD68, CA5B | HPGD 926/4885HTT 1441/4885SMN1; SMN2 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.